Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.56 |
| ▸ | OSBP | P22059 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13425371 | 0.99 | BACE1 (0.57) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL30392240 | 0.92 | OSBP (0.58) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL30392605 | 0.91 | BACE1 (0.59) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL24075562 | 0.88 | PTGES (0.57) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL12846394 | 0.88 | BACE1 (0.48) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL16224898 | 0.87 | PPARG (0.53) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL8011241 | 0.83 | BACE1 (0.79) | BACE1APPPTPN1MAOBPTGES | |
| SCHEMBL30574448 | 0.83 | BACE1 (0.55) | BACE1OSBPAPPPTPN1MAOB | |
| SCHEMBL16224896 | 0.83 | BACE1 (0.54) | BACE1APPPTPN1MAOBPTGES | |
| SCHEMBL23484273 | 0.83 | BACE1 (0.51) | BACE1OSBPAPPPTPN1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-9144539-B2 | Methioninase inhibitor and composition and food or drink containing the same | Lotte Co, Ltd. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9144539-B2 | Methioninase inhibitor and composition and food or drink containing the same | Lotte Co, Ltd. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140308218-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | LOTTE CO LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-20140308218-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | LOTTE CO LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8232318-B2 | Approaches to treat cancer using HB-EGF inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2011014257-A9 | APPROACHES TO TREAT CANCER USING HB-EGF INHIBITORS SUCH AS MYRSINOIC ACID A | THE GENERAL HOSPITAL CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060047-A1 | APPROACHES TO TREAT CANCER USING HB-EGF INHIBITORS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100069477-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | LOTTE CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069477-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | LOTTE CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | BACE1 4695/4885OSBP 3999/4885APP 4876/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | BACE1 4695/4885OSBP 3999/4885APP 4876/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | BACE1 4695/4885OSBP 3999/4885APP 4876/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | BACE1 3266/4885OSBP 3881/4885APP 4120/4885 |
| US-20100069477-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | MAT2A, SMS, MAT2B | BACE1 1819/4885OSBP 2077/4885APP 3296/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | BACE1 4695/4885OSBP 3999/4885APP 4876/4885 |
| US-20140308218-A1 | METHIONINASE INHIBITOR AND COMPOSITION AND FOOD OR DRINK CONTAINING THE SAME | MAT2A, SMS, MAT2B | BACE1 1819/4885OSBP 2077/4885APP 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.